Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q1 EPS of ($0.91), $0.06 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $17.39 million versus the consensus estimate of $9 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.